The dangerous part may be smaller than a grain of sand. During transcatheter aortic valve replacement, a cardiologist threads a new valve into a diseased heart without opening the chest. The hardware passes through an aorta often crusted with calcium. Tissue, thrombus and mineral fragments can break loose. Blood then supplies the getaway car, carrying that debris toward the vessels that feed the brain.
This is the narrow problem Transverse Medical has chosen to live inside. The Denver company is developing POINT-GUARD, a temporary cerebral embolic protection device. Before the valve work begins, the filter is delivered by catheter and positioned inside the aortic arch. It is designed to cover the openings of all three great arch vessels. Debris meets mesh instead of cerebral circulation; when the work is finished, the filter and its catch are removed.
The sentence is tidy. The anatomy is not. Arches differ in diameter, angle and branch placement. The filter must seal across those variations, remain stable in pulsing blood, avoid scraping a vessel wall, and coexist with the much larger tools doing the main job. A protection device that blocks the operator is its own kind of complication. POINT-GUARD’s commercial promise, if its clinical program bears it out, is therefore twofold: more complete coverage for the patient and less procedural friction for the physician.
A safety system for the main event
TAVR has transformed treatment for aortic stenosis by replacing a narrowed valve through a catheter. Yet the procedure creates a peculiar split-screen outcome: the valve can be seated successfully while dislodged particles cause a clinical stroke or quieter brain injury. Cerebral embolic protection sits beside the primary therapy, more seat belt than engine. It does not repair the valve. It exists because repairing the valve can create another risk.
The likely users are structural-heart teams, particularly interventional cardiologists. Hospitals and health systems would be the buyers if the device wins clearance. Patients are the beneficiaries, but they will not shop for POINT-GUARD. Adoption would depend on physicians finding it safe, fast and predictable, hospital committees accepting its cost, and clinical evidence showing that the extra step changes outcomes enough to justify routine use.
This makes Transverse a hardware company in a market governed by evidence. It has no approved product to sell today. Its current output is accumulated proof: engineering runs, patents, physician feedback, manufacturing processes, clinical cases and regulatory submissions. The eventual business would most likely be procedure-by-procedure sales of disposable systems to hospitals, either through its own commercial operation or a larger strategic partner. Pricing and distribution have not been disclosed.
The geometry of “full”
Boston Scientific’s Sentinel is the established commercial reference point in the United States. Introduced through the arm, its two filters protect the brachiocephalic and left common carotid arteries. That leaves the left subclavian artery outside the system’s direct coverage. POINT-GUARD is designed as a broad filter across all three openings. Its frame is intended to adapt to the arch, form a double-edge seal, and stabilize itself without crowding the valve-delivery equipment.
That is the central point of difference, but not a monopoly on ambition. TriGuard, ProtEmbo, Emboliner, Captis and Emblok represent other attempts at broader or differently configured embolic protection. They vary in access route, filter versus deflection, pore size, capture territory and regulatory progress. The other competitor is no device at all. Any new protection system must persuade clinicians that adding hardware and time reduces more risk than it introduces.
“Point-Guard was easy to use, simple to deploy and retrieve.”Dr. Robert Gooley, physician investigator
Gooley’s observation followed the first series of feasibility-study procedures at Victorian Heart Hospital in Melbourne in 2025. Transverse reported no device-related adverse events in that initial phase and described positioning as predictable. Those are encouraging operational observations, not a verdict on clinical benefit. The registered GUARDIAN study is prospective, single-arm, open-label and small. Its role is to establish early performance and safety, refine technique and prepare the ground for larger trials.
POINT-GUARD is investigational. It is not approved by the US Food and Drug Administration, is not cleared for sale, and should not be confused with a commercially available therapy.
Five patients beat sixty prototypes
Transverse’s development history is more revealing than a polished product animation. Eric Goslau, a medtech sales executive turned founder, began the company around 2011. He had worked with engineer Brad Lees at Cordis and Spectranetics. Lees began thinking about cerebral protection after his father-in-law suffered a stroke following a coronary intervention. The personal observation became a product thesis: if the procedure releases debris, protect the exits to the brain.
The team built roughly 50 to 60 prototypes and tested in 26 animals before taking a first-generation device into a small first-in-human experience in Germany. Five patients then revealed what models had not. Human aortic anatomy created gaps and fit problems that demanded another design cycle. In 2019 the company began reworking POINT-GUARD. The pandemic slowed financing and development; a Colorado Advanced Industries grant and support from existing investors helped it continue.
“The evil of good is great.”Eric Goslau, on the danger of polishing too long before clinical learning
It is an odd phrase with a practical meaning. A team can improve a device forever on a bench and still miss the thing a body will teach in five minutes. Goslau’s favored loop is staged: build enough, test early, learn from real use, then improve. That philosophy carries risk and must stay inside ethical and regulatory guardrails. It also acknowledges medtech’s least forgiving equation - every month consumes capital, while only credible evidence moves the product closer to patients.
Translate an anatomical problem into a frame, filter, catheter and deployment sequence.
Use bench models and preclinical work to challenge seal, stability, flow and retrieval.
Observe the anatomical variation and operator behavior that models cannot fully reproduce.
Refine the system, expand clinical study and prepare a regulatory case for clearance.
Capital with a long memory
The financing has been equally iterative. Public accounts describe early equity, debt and grant support, then a $3 million Series B1 in 2023 to prepare manufacturing and the feasibility program. In April 2025, Transverse announced more than $10 million in Series B2 capital. The lead was not named, described only as a long-standing family office, with participation from B1 investors.
That structure says something about the company’s culture. This is a small team built around specialists rather than scale for its own sake: engineering, regulatory, clinical, quality and veteran physician advisers. Leadership materials repeatedly emphasize working beside operators and key opinion leaders. Ian Meredith, the former global chief medical officer of Boston Scientific and an experienced interventional cardiologist, joined the board in 2024. Thomas Chilcott, a finance executive with public-market and life-sciences experience, became CFO in June 2026.
The B2 money was earmarked for continued clinical validation, platform development, operational infrastructure and hiring, as well as preparation for pivotal trials and a US investigational device exemption submission. In other words, it financed the next set of questions. Does the device fit enough anatomies? Can different physicians deploy it reproducibly? Are safety signals acceptable? And, eventually, does complete coverage produce better neurological outcomes than partial coverage or no protection?
Where the company fits
Transverse sits at the intersection of structural heart and neuroprotection. It is not competing to replace the TAVR valve. It wants to become part of the procedure’s safety stack, a category that could grow as treatment expands to younger and lower-risk patients who may be less willing to accept preventable brain injury. The opportunity also creates a high bar. A preventive device must demonstrate benefit against events that are serious but relatively infrequent, and it must do so without adding complications of its own.
The company’s larger platform language hints at applications beyond TAVR and into other left-sided cardiovascular procedures where embolic debris is a concern. For now, that is a horizon, not a commercial line. POINT-GUARD and its clinical program remain the business. The most credible measure of progress will not be another rendering of a filter. It will be clean deployment across varied anatomies, a convincing safety record and comparative evidence that shows where captured debris would otherwise have gone.
There is something modest about the device’s role. If it works as intended, the cardiologist retrieves a dirty filter and the patient may never know what failed to reach the brain. The valve gets the photograph. The net gets the particles. Transverse Medical is trying to build a company around that quiet difference.